NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco
California
94080
United States
125 articles with NGM Biopharmaceuticals, Inc.
-
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
3/1/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 43rd Annual Health Care Conference as part of the Novel Oncology Targets Panel and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Tuesday, March 7th, at 9:10 am ET.
-
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
2/28/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the fourth quarter and full year ended December 31, 2022.
-
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
1/12/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Siobhan Nolan Mangini, President and Chief Financial Officer, will participate in the B. Riley Securities 3rd Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 19th, at 11:00 am ET.
-
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
1/9/2023
NGM Biopharmaceuticals, Inc. is providing an overview of highlights from 2022 and outlining its 2023 corporate priorities.
-
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
12/12/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail today on the poster presentation given on the Company’s first disclosed preclinical bispecific program, NGM936, at the American Society of Hematology (ASH) Annual Meeting.
-
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
12/7/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced the presentation of preliminary data from the Phase 1 Part 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Annual Congress, which is taking place December 7 – 9, 2022 in Geneva, Switzerland.
-
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
11/7/2022
NGM Biopharmaceuticals, Inc. announced that an abstract related to the Company’s lead myeloid reprogramming and checkpoint inhibition program, NGM707, has been accepted for presentation at the European Society for Medical Oncology Immuno-Oncology Annual Congress, which will take place December 7 – 9, 2022 at the Palexpo Exhibition Centre in Geneva, Switzerland.
-
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
11/3/2022
NGM Biopharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarterly period ended September 30, 2022.
-
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
11/3/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced the presentation of findings from post-hoc analyses of its randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621, a monoclonal antibody designed to inhibit activity of complement component 3 (C3), in patients with GA secondary to AMD at The Retina Society Annual Scientific Meeting taking place November 2 – 5, 2022 in Pasadena, Calif.
-
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
10/17/2022
NGM Biopharmaceuticals, Inc. today announced topline efficacy and safety results from its randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
10/16/2022
NGM Biopharmaceuticals, Inc. will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration.
-
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine & Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer
9/13/2022
NGM Biopharmaceuticals, Inc. announced that updated preliminary findings from its Phase 1b dose escalation trial of NGM120, a novel GFRAL antagonist antibody drug candidate, in patients with metastatic pancreatic cancer are being presented at the American Association for Cancer Research Special Conference: Pancreatic Cancer, on Wednesday, September 14, 2022.
-
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress
9/6/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), today announced that updated preliminary findings from its open-label Phase 1a dose escalation study of NGM120, a novel GFRAL antagonist antibody drug candidate, in a subset of patients with advanced prostate cancer will be presented at the European Society for Medical Oncology (ESMO) Annual Congress on Sunday, September 11, 2022.
-
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
8/4/2022
NGM Biopharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarterly period ended June 30, 2022.
-
Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.
-
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
6/30/2022
William J. Rieflin to transition from Executive Chairman to Chairman of the Board of Directors.
-
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
6/23/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the fourth of four virtual R&D events on Wednesday, June 29, 2022, from 11:00 am – 12:30 pm ET.
-
NGM Bio to Participate in Upcoming Investor Conferences - June 02, 2022
6/2/2022
NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.
-
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
5/24/2022
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced it will host the third of four virtual R&D events on Tuesday, May 31, 2022, from 12:00 pm – 1:15 pm ET.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.